Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 7/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.47 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.39 |
| ▸ | ULK1 | O75385 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519193 | 0.87 | PDCD1 (0.45) | PDCD1CD274CNR2 | |
| SCHEMBL20519192 | 0.87 | PDCD1 (0.45) | PDCD1CD274CNR2 | |
| SCHEMBL20519001 | 0.79 | CNR2 (0.52) | PDCD1CD274CNR2TAS1R3TAS1R1 | |
| SCHEMBL20519003 | 0.79 | CNR2 (0.52) | PDCD1CD274CNR2TAS1R3TAS1R1 | |
| SCHEMBL20524393 | 0.79 | CNR2 (0.39) | PDCD1CD274CNR2 | |
| SCHEMBL1458785 | 0.74 | P2RX7 (0.41) | PDCD1CD274CNR2 | |
| SCHEMBL14136595 | 0.74 | CNR2 (0.41) | PDCD1CD274CNR2MEN1KMT2A | |
| SCHEMBL15033682 | 0.74 | METAP2 (0.46) | PDCD1CD274MEN1KMT2A | |
| SCHEMBL1459953 | 0.73 | MAPK1 (0.47) | — | |
| SCHEMBL1459777 | 0.73 | NPC1 (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678466-B | Diazanaphthalenes as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-110678466-A | Naphthyridines as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | PDCD1 524/4885CD274 2378/4885CNR2 4556/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | PDCD1 524/4885CD274 2378/4885CNR2 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.